| Literature DB >> 31963211 |
Ehsan Bahojb Noruzi1, Behrouz Shaabani1, Silvano Geremia2, Neal Hickey2, Patrizia Nitti2, Hossein Samadi Kafil3.
Abstract
The design and synthesis of a novel tert-butyl-calix[4]arene functionalizedEntities:
Keywords: X-ray structure; anticancer; antimicrobial; calix[4]arene; metal complex; thiosemicarbazone
Year: 2020 PMID: 31963211 PMCID: PMC7024204 DOI: 10.3390/molecules25020370
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1The route for synthesis of L. Reaction conditions: (i) Chloroacetonitrile, K2CO3, NaI, reflux, 7h (ii) LiAlH4, (0 °C), 4h (iii) CSCl2, BaCO3, 24h (iv) Hydrazine hydrate, room temperature, 3 h.
Figure 1Selected portion of the 1H-NMR spectrum of ligand L.
Figure 2Solid-state structure of L. (a) The molecule shows a cone conformation. (b) Orthogonal view of L with respect to the calix[4]arene mean plane (yellow) defined by the methylene bridging groups. (c) The two enantiomeric conformations of L observed in the centrosymmetric crystal structure. Hydrogen atoms have been omitted for clarity.
Summary of the main short interactions found in the structure of L.
| D •••A a | d (D•••A) (Å) |
|---|---|
|
| |
| O(1B)•••O(1A) | 2.871 |
| O(1D)•••O(1C) | 2.922 |
|
| |
| O(2A)•••N(3A) | 2.710 |
| O(2C)•••N(3C) | 2.742 |
|
| |
| N(1A)•••O(1W) | 2.978 |
| N(1C)•••O(1W) | 3.185 |
| O(2A)•••O(1W) | 2.850 (phenol hydroxy) |
| O(2C)•••O(1W) | 3.051 (phenol hydroxy) |
|
| |
| O(1D)•••O(1W) | 2.872 (hydroxy) |
| O(1B)•••O(1W) | 2.986 (hydroxy) |
| O(1C)•••O(1W) | 3.094 (alkoxy) |
| O(1A)•••O(1W) | 3.258 (alkoxy) |
a The atom labels in parenthesis are those used in the deposited structure. b For clarity, the type of non-water oxygen atom involved is identified in parenthesis.
Antibacterial activity of synthesized compounds against different microorganisms in the micro-broth dilution method. The antibacterial activity is expressed as the MIC/MBC (μg/mL).
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Ligand | - | 31.25 | 31.25/31.25 | 31.25/- | 31.25/125 | - |
| Complex | - | 31.25/1000 | 31.25/31.25 | 31.25/250 | 62.5/- | - |
| Complex | - | 31.25 | 31.25/31.25 | 31.25/2000 | - | - |
| Complex | 31.25 | 31.25 | 31.25/31.25 | 31.25/500 | - | - |
| Complex | - | 31.25 | 31.25/31.25 | 31.25/31.25 | - | - |
| Gentamicin * | 0.12/0.25 | 2/2 | 0.5/0.5 | 2/2 | - | - |
| Nystatin * | - | - | - | - | 1.25 | 0.625 |
Staphylococcus aureus (ATCC® 29213™), Bacillus subtilis (ATCC® 6633™), Escherichia coli (ATCC® 25922™), Pseudomonas aeruginosa (ATCC® 27853™), Candida albicans (ATCC® 10231™), and Candida glabrata (ATCC® 2001™). * Gentamicin and nystatin used as a standard control for bacteria and fungi, respectively.
Figure 3Cytotoxicity evaluation of synthesized compounds at various concentrations against cancer cell lines; (A) (MG-63 cell lines), (B), and (C) (Saos-2 cell lines). Cytotoxicity evaluation of MTX and DOX at various concentrations against MG-63 (D) and Saos-2 (E) cell lines.
In vitro cytotoxic activity IC50 (μg/mL) of compounds against bone cancer cell lines.
| Compound | Saos-2 | MG-63 |
|---|---|---|
| Ligand | <25 | >200 |
| Complex | 80 | 195 |
| Complex | 62 | 173 |
| Complex | 43 | 140 |
| Complex | >200 | >200 |
| MTX | 7.9 | 14.5 |
| DOX | 2.1 | 10.1 |
Figure 4Fluorescent microscopic images of DAPI-stained cells following 48-h treatment with A (fresh medium (control)), B (ligand L), C (complex Co2+), D (complex Ni2+), E (complex Cu2+), and F (complex Zn2+). Red circles indicate the Saos-2 nuclei with anomalous morphology after internalization of the fluorescent chemical compounds (L, and complexes of Co2+, Ni2+, Cu2+, and Zn2+).
Figure 5Hemolysis rate of HRBCs in the presence of synthesized compounds at different concentrations (A). Optical images of HRBCs treated with synthesized compounds (at the concentration of 200 μg/mL) under light microscopy (B).